Document Detail

Diagnostic and prognostic utility of the serum free light chain assay in patients with AL amyloidosis.
MedLine Citation:
PMID:  17547724     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Organ dysfunction in AL amyloidosis is related to the production and deposition of amyloidogenic monoclonal light chains. These pathological light chains can now be quantified using the recently developed serum free light chain assay. METHODS: We retrospectively reviewed 31 patients with AL amyloidosis to determine the frequency of abnormal free light chain assay results at diagnosis and whether changes in the serum free light chain assay predict outcome after therapy. RESULTS: An abnormal free light chain assay was found in 30 of 31 patients (97%) at the time of diagnosis. In the subset of our patients who received treatment for AL amyloidosis, a >50% reduction of the pathological free light chain following treatment was shown to predict improved overall survival. In our series of analyses, achievement of greater magnitudes of reduction of the free light chain result did not appear to provide additional prognostic information, nor did the baseline free light chain result predict outcome. CONCLUSION: Our findings support the use of the free light chain assay in the diagnostic work-up of patients with suspected AL amyloidosis, and also as a sensitive biomarker of response to therapy.
K L Morris; J R Tate; D Gill; G Kennedy; J Wellwood; P Marlton; R Bird; A K Mills; P Mollee
Related Documents :
10154654 - The demand for alcohol: the differential response to price.
6808024 - Light chain composition of csf oligoclonal igg bands in multiple sclerosis and subacute...
23093754 - A variable ultra-short-pathlength solution cell for xafs transmission spectroscopy of l...
3918454 - Glomerular capillary aneurysms in light-chain nephropathy. an ultrastructural proposal ...
11730104 - Electromagnetic perception and individual features of human beings.
1873584 - Optimization of a slow-acting automatic gain control system for use in hearing aids.
Publication Detail:
Type:  Clinical Trial; Journal Article    
Journal Detail:
Title:  Internal medicine journal     Volume:  37     ISSN:  1445-5994     ISO Abbreviation:  Intern Med J     Publication Date:  2007 Jul 
Date Detail:
Created Date:  2007-06-05     Completed Date:  2007-07-02     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101092952     Medline TA:  Intern Med J     Country:  Australia    
Other Details:
Languages:  eng     Pagination:  456-63     Citation Subset:  IM    
Department of Clinical and Laboratory Haematology, Queensland Health Pathology Service, Princess Alexandra Hospital, Woolloongabba, Queensland, Australia.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Amyloid / blood*
Amyloidosis / blood*,  drug therapy
Biological Markers / blood
Immunoglobulin Light Chains / blood*
Middle Aged
Retrospective Studies
Sensitivity and Specificity
Treatment Outcome
Reg. No./Substance:
0/Amyloid; 0/Biological Markers; 0/Immunoglobulin Light Chains; 0/amyloid fibril protein AL

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Prevalence of thyroid disease in an older Australian population.
Next Document:  Clinical perspectives in lymphoma.